Abstract. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential anti-cancer agents for the treatment of solid and hematological malignancies. However, the best characterized HDAC function concerns the control of gene expression via the regulation of transcription activation or repression. To understand the genome-wide effects of HDAC inhibition on gene regulation, we performed serial gene expression analyses from 0 to 48 h after treating MDA-MB-435, a melanoma-derived highly metastatic tumor cell line, with Apicidin, a HDAC inhibitor. Combined-transcriptomic analysis of large-scale molecular changes induced by Apicidin resulted in the identification of 631 outlier genes that were continuously up-or down-regulated during the 48 h study period. When the 631 outlier genes were mapped to known biological processes, cell-cycle suppression emerged as the function most elicited by Apicidin. In addition comprehensive negative cell-cycle regulation by Apicidin was dissected using gene expression data and validated by Western blot analysis. We suggest the 631 outlier genes as a characteristic molecular signature for Apicidin, and propose concurrent transcriptional suppression of major components of cell-cycle regulatory circuit as potent anti-tumor mechanism of Apicidin. Genetic elements identified during this study also provide the possibility of novel therapeutic interventions in tumor metastasis.
Introduction
Aberrant gene regulation plays an important role in tumor initiation and progression, and methods designed to correct this dysfunction constitute new anti-cancer strategies (1) . The acetylation status of lysine residues in nucleosomal histone proteins is known to play a crucial role in chromatin structure and gene transcription (2) . Histone deacetylases (HDACs) and the family of histone acetyltransferases (HATs) are involved in the determination of the acetylation of histones, which are known to participate in the regulation of gene expression (3) . HDACs are known to play important roles in the regulation of gene transcription, and as such, are involved in key biological processes during cell proliferation, differentiation, and survival (4) (5) (6) . Although no clear evidence has been presented demonstrating that HDAC alterations are directly associated with human cancer, class I and II HDACs have been reported to be associated with several well-known oncogenes and tumor suppressors (7) . For example, the repression of tumor suppressor genes is known to promote carcinogenesis (8) , and multi-protein complexes that contain DNA binding protein commonly use HDACs to repress transcription and block the functions of tumor suppressors.
Recently, HDAC inhibitors have emerged as promising chemotherapeutic agents, and the findings of several studies suggest that they can induce a range of anti-tumor activities including the induction of cell-cycle arrest, the stimulation of differentiation, and the provocation of apoptosis in a variety of transformed cells in culture and tumor bearing animals (3, 4, 7, 9) . Unlike conventional chemotherapeutic agents that often cause DNA damage in tumor and normal tissues, HDAC inhibitors display strong selectivity and are less toxic to normal tissues (3) . However, the mechanisms underlying this tumor selectivity are not fully understood. During recent years, increasing numbers of structurally diverse HDAC inhibitors have been identified that inhibit the proliferation and induce the differentiation and/or apoptosis of tumor cells in vitro and in vivo. Actually, several natural and synthetic compounds including n-butylate, trapoxin, trichostatin A (TSA), depudecin, and MS-27-275 can inhibit HDAC (10) . The efficacies of these agents, particularly of TSA and suberoylanilide hydroxamic acid (SAHA), have been established by in vitro experiments and ongoing clinical trials (9, 11) . Furthermore, some HDAC inhibitors, such as valproate and depsipeptide (FR901228) are currently undergoing phase II clinical trials (12, 13) .
Apicidin [cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-L-2-amino-8-oxodecanoyl)], a recently studied HDAC inhibitor, has been reported to be a potent and universal inhibitor of HDACs and to exhibit anti-tumor effects (e.g. inhibition of cell proliferation). In addition, these anti-tumor activities have also been observed in vitro for different cancer cell lines (14, 15) . Apicidin was first described as anti-cancer agent that suppressed HeLa cell growth by inducing p21 WAF1/Cip1 (15) . However, no attempt has been made to portray the molecular circuit responsible for anti-tumor mechanism via HDAC inhibition in tumor cells. The present study describes large-scale molecular changes at the transcriptomic level and provides insight into the systemic anti-neoplastic mechanisms responsible of inhibiting HDACs, based on a study of the effects of Apicidin, a potent HDAC inhibitor, on MDA-MB-435 cells.
Materials and methods
Cell culture. MDA-MB-435 cell line derived from the melanoma cell line M14 was obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in appropriate culture media supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA), and 1% penicillin/streptomycin (Gibco Industries Inc., Carlsland, CA, USA). The cultures were maintained in a 5% CO 2 humidified atmosphere at 37˚C.
Apicidin treatment. Apicidin [cyclo(N-O-methyl-Ltryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxode canoyl)] was purchased from Calbiochem
® (Merck KGaA, Darmstadt, Germany). MDA-MB-435 cells were harvested and seeded at 1.5x10 5 cells in a 60-mm dish, and allowed to grow in complete growth media (DMEM/10% FBS) overnight at 37˚C in a 5% CO 2 humidified incubator. Cells were then treated with the indicated amounts of Apicidin for cell growth and apoptosis experiments. For comprehensive genomic analysis, Apicidin (1 μg/ml) was added at the above-mentioned time points into MDA-MB-435 cells and, RNAs of cells treated with Apicidin for the above-mentioned times were subjected to DNA microarray analysis.
Antibodies. Antibodies against PARP, p21, CDK2, CDK4, were purchased from Cell Signaling (Cell Signaling Technology, Danver, MA, USA). Antibodies against DP-1, E2F1, HDAC1, ß-actin were obtained from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and antibodies against histone H4, ·-tubulin, and acetyl-histone H4 were purchased from Upstate (Upstate Biotechnology, Lake Placid, NY, USA).
Apoptosis assays. MDA-MB-435 cells were plated at a density of 1.5x10 5 cells/plate and treated with Apicidin at the abovementioned concentrations for 4 days in a 60-mm dish. Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences, San Diego, CA, USA) was used to quantify levels of apoptosis induced by Apicidin. Briefly, cells were trypsinized, centrifuged and resuspended in binding buffer at 1x10 6 cells/ ml, and 5 μl of Annexin V-FITC and 5 μl of PI were added to 100 μl of the suspension (~1x10 5 cells). Cells were then incubated at RT for 15 min in the dark, and analyzed by flow cytometry (FACS Vantage SE Flow Cytometric system; Becton-Dickinson, Franklin Lakes, NJ, USA).
Cell growth assays. Cells were seeded at 1x10 5 cells/well in 6-well plates, and 24 h later, a stock solution of Apicidin in ethanol was added to concentrations of 0, 0.5, 1, or 2 μg/ml. At the above-mentioned time points, viable cells were counted using the Trypan blue exclusion method. All experiments were conducted in triplicate.
Western blot analysis. After being treated with Apicidin, whole cells were washed twice in ice-cold PBS and lysed with 200 μl of RIPA buffer [50 mM Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 tablet/50 ml of protease inhibitor cocktail (Roche, Mannheim, Germany)]. Protein concentrations in whole cell lysates were determined using BCA protein assay reagent (Pierce, Rockford, IL, USA), and 20 μg aliquots of proteins were subjected to SDS-polyacrylamide gel electrophoresis, and then transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Piscataway, NJ, USA). Membranes were blocked with Tris-buffered saline (TBS) containing 0.1% Tween-20 and 5% (w/v) dried skimmed milk powder and incubated in fresh blocking solution containing primary antibodies at appropriate dilutions for 1 h at RT. Blots were then washed three times for 5 min in TBS-T, incubated with a 1:5000 dilution of horseradish peroxidase-conjugated 2nd antibody (Pierce) for 1 h at RT, and rewashed (3x5 min) in TBS-T. The protein-antibody reactions were detected using ECL detection kits (Amersham Biosciences).
Large-scale analysis of gene expression profiling using oligonucleotide arrays. Microarray analysis was performed using human DNA microarrays manufactured by the Microdissection Genomics Research Center, College of Medicine, The Catholic University of Korea. Microarrays contained approximately 19000 genetic elements (16) . In brief, total cellular RNA was extracted from Apicidin-treated cells using TRIzol ® reagent (Gibco Industries Inc.). Total RNA was quantified with NanoDrop (NanoDrop Technologies, Wilmington, DE, USA). RNA qualities were checked using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) and intact RNA samples (260/280 ratio >1.8) were used for hybridization. Human universal reference RNA (Stratagene, La Jolla, CA, USA) was used as a reference RNA. For each RNA sample, 20 μg of total RNA was primed with Oligo(dT) and labeled with Cy3-dUTP or Cy5-dUTP (NEN, Boston, MA, USA) during reverse transcription. Labeled cDNA targets were concentrated to ~15 μl using a Microcon-YM30 (Amicon, Bedford, MA, USA). Hybridization was carried out at 42˚C for 16 h using the MAUI Hybridization System (BioMicro Systems, Salt Lake City, UT, USA). After hybridization, microarrays were washed with the following buffers; 2X standard sodium citrate (SSC) and 0.1% SDS for 2 min (twice), 1X SSC and 0.1% SDS for 3 min, 0.2X SSC for 3 min, 0.05X SSC for 2 min, and finally rinsed with distilled water for 2 min.
Scanning and data analysis. The arrays with hybridized targets were scanned using an Axon scanner and images and analyzed using GenePix ® Pro 4.1 software (Axon Instruments, Foster City, CA, USA). Spots of poor quality, as determined by visual inspection, were excluded from further analysis. Resulting array data were submitted to the BioArray Software Environment (BASE) database at the microarray core facility at the Department of Pathology, College of Medicine at The Catholic University of Korea (http://genomics.catholic.ac.kr/). Data were normalized using the LIMMA package (Linear Models for Microarray Data) and the R-package of SMA (Statistics for Microarray Analysis). Spots of less than 50 μm were excluded from analysis, if none are specified. Pearson's correlation coefficients were calculated using S-PLU, and Cluster and TreeView were used for data visualization (17) . Pathway analysis was performed with ArrayXPath (http://www.snubi. org/software/ArrayXPath/).
Results

Anti-mitogenic effects of Apicidin on MDA-MB-435 cells.
Previous studies have shown that Apicidin strongly inhibits HDAC activity in cell lines from various tissues, and that it induces the accumulation of acetylated histones in vivo (15, 18, 19) . The MDA-MB-435 cell line was derived from the melanoma cell line M14, which showed highly metastatic potential in animal model experiments (20) . To determine whether Apicidin has similar effects on highly metastatic cancer cells, we initially assessed intracellular HDAC levels in MDA-MB-435 cells. Eight different classes of HDACs (HDAC1-8) were found to be expressed in MDA-MB-435 cell lines (data not shown).
The morphological change induced by Apicidin in vitro is a hallmark of its anti-tumor effect on cancer cells (15) . As shown in Fig. 1A , MDA-MB-435 cells became elongated with filamentous protrusion when they were treated with increasing concentrations of Apicidin (0.5-2 μg/ml). When cellular growth rate was assessed with the same concentration of Apicidin, it was dramatically reduced by Apicidin treatment (Fig. 1B) . The functional significance of this cell growth inhibition was confirmed by FACS analysis after staining Apicidin treated cells with Annexin V-FITC. As shown in Fig. 1C , the proportion of apoptotic cells was increased from 5.4% to 19% at 48 h after treatment of Apicidin (2 μg/ml). Previous reports have suggested that Apicidin induces apoptosis via cytosolic cytochrome c release by selectively inducing Fas/Fas ligand and the activations of caspase-9 and caspase-3 (15, 21) . To confirm the mechanism of apoptotic cell death by Apicidin, PARP cleavage was analyzed. As shown in Fig. 1D , endogenous PARP cleavage fragments (85 kDa) were detected by treatment with Apicidin at <1.0 μg/ ml for 48 h, and accumulated in a dose-dependent manner.
Identification of the characteristic molecular signature of Apicidin. To understand transcriptomic regulation by Apicidin in MDA-MB-435 cells, cells were treated with Apicidin (1 μg/ml) for different time points and each cell lysate was subjected to DNA microarray containing approximately 19,000 human genetic elements (see Materials and methods). Next, we designed the following algorithms for the large-scale gene expression analysis to recapitulate specific molecular signature induced by Apicidin. Essentially, the algorithm was subtracting gene expression level of non-treated control (0 h) from that of experiment at each time point. Genes having the value greater than two in fold change were selected. As a result, the 631 genes were selected and then displayed as a heatmap to view a molecular signature of Apicidin ( Fig. 2A) . Our heatmap result showed that the expressions of 198 genes continuously decreased, and the expressions of 433 genes continuously increased after Apicidin treatment (Table I ). In addition, the expressions of some genes were changed rapidly after exposure to Apicidin (Fig. 2A) .
We attempted to determine the functional nature of the 631 selected genes using a pathway mining tool, ArrayXPath, which maps the selected 631 outlier genes into intracellular molecular pathways. Application of this software revealed that genes affected by Apicidin treatment were mostly involved in cell-cycle signaling pathways (data not shown). Eleven of the 631 genes (SMAD3, HDAC5, ORC4L, CDC2, MCM5, PCNA, MCM7, TFDP1, E2F1, CCNB1, CDK4) were mapped to cell-cycle pathways, and their expression changes with time are depicted as a heatmap and a line-graph in Fig. 2B and C, respectively. SMAD3, a downstream effector molecule in TGF-ß receptor signaling, was highly activated by Apicidin, Table I . Continued.
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but genes involved in G1/S cell-cycle progression and DNA replication (CDC2, MCM5, MCM7, PCNA, E2F1 and CDK4) were suppressed ( Fig. 2B and C) .
Molecular dissecting of cell-cycle regulation by
Apicidin treatment through large-scale data analysis. We asked whether this regulation of genes in the cell-cycle signaling pathway is specifically mediated by Apicidin or its cytotoxicity. Accordingly, we displayed the gene expression levels of all selected genes associated with the regulation of G1/S cellcycle progression on a heatmap (Fig. 3A) . For example, the SMADs are a class of proteins that modulate the activities of transforming growth factor ligands, and cytoplasmic SMADs form complexes and then translocate to the nucleus, where they serve as transcription factors. As shown in Fig. 3A , the expression level of SMAD3 was immediately induced by Apicidin, whereas SMAD4 was up-regulated after 24 h of treatment. Inhibitors of cyclin-dependent kinases (CDKs), such as p21 Cip1 , p27 Kip1 and p57 Kip2 are important molecules that negatively regulate cell-cycle progression through G1/S transition. It appeared that p21 Cip1 was specifically induced by Apicidin, and CDK2 and CDK4 (but not the other CDKs) were specifically down-regulated by Apicidin (Fig. 3A) . These results were also confirmed at the protein level by Western blotting (Fig. 3B) . Furthermore, cyclin A2, B1, B2 and cell division cycle 2 (CDC2) were specifically down-regulated by Apicidin, but the other cyclins and CDCs were not. In fact, cyclin A, B and CDC2 are also major regulators in the G2/M rather than the G1/S transition, implying that Apicidin affects cell-cycle progression by modulating the expressions of core components of the cell-cycle clock.
In G1/S cell-cycle transition, activation of CDKs/cyclins complexes phosphorylates retinoblastoma (Rb) protein, which can no longer suppress E2F/DP-1, and leads to the transcriptional activation of downstream target molecules. As shown in Fig. 3A , among the E2F family members, only E2F1 was suppressed by Apicidin. It appears that some of the E2F/DP-1 downstream target genes, such as MCMs, PCNA, and DHFR, were down-regulated by Apicidin. Interestingly, some HDAC genes were specifically shown to be induced by Apicidin (Fig. 3A) .
Discussion
Gene expression is in part regulated by the differential acetylation of nucleosomal histones, whereby hyperacetylation causes transcriptional activation and hypoacetylation causes repression (8, 22, 23) . This phenomenon is regulated tightly by the balance between the activities of HAT and HDAC. In general, histone acetylation causes a more open chromatin structure, which facilitates transcriptional activation. HDACs can act as transcription repressors, due to histone deacetylation, and consequently promote chromatin condensation. Furthermore, HDAC inhibitors selectively alter gene transcription, in part, by causing chromatin remodeling and by changing the structures of proteins in transcription factor complexes (24) . Eighteen HDAC enzymes have been identified and classified in human, based on homologies with yeast HDACs (25, 26) . The class I HDACs include HDAC1, 2, 3 and 8, which are related to yeast RPD3 deacetylase and have high homologies at their catalytic sites (27) . Class II HDACs are related to yeast Hda 1 (histone deacetylase 1) and include Table I . Continued. 
HDAC4, 5, 6, 9 and 10, which contain two catalytic sites (26, 27) . The human class III Sir2 or Hsts, SIRTs (sirtuins) and Sir-related proteins, are related to HDACs in yeast (28) , and class IV HDAC is represented by HDAC11, as conserved residues in the catalytic core region shared by both class I and II enzymes (29) . A wide range of molecules, both natural and synthetic, have been identified that can inhibit the activities of class I, II and IV HDACs (1, 30) . With a few exceptions, these can be categorized as hydroxamic acid and its derivatives, carboxylates, benzamides, electrophilic ketones, and cyclic peptides (31, 32) . In particular, Apicidin is a fungal metabolite and an anti-protozoal agent that inhibits HDACs (14) .
Although previous studies have shown that Apicidin has an anti-proliferative effect on various cancer cell lines (10,15,21) , few studies have examined its effects in highly metastatic cancer cells, such as MDA-MB-435 cells. In addition, because HDAC inhibitors are known to alter global gene expression, it was of interest to determine its effects on gene expression in carcinoma cells. Therefore, to understand the genomic effects of Apicidin on MDA-MB-435 cells, we investigated the anti-proliferative activity of Apicidin and its effects on global gene expression profiles. Our results show that Apicidin has potent anti-tumor effects on MDA-MB-435 cells (Fig. 1) and we identified 631 genes showing altered expressions by at least 2-fold through performing a largescale serial data analysis (Fig. 2) . In addition, the pathway mining analysis of these 631 genes suggested that Apicidin causes cell-cycle arrest by activating negative cell-cycle regulators and/or inactivating cell-cycle accelerating molecules at the transcriptional level (Figs. 2 and 3) .
There have been some reports that the time of culture and/or concentration of HDAC inhibitor used affect the number of genes detected with altered transcription. That is, short time points and low concentration cause fewer changes in gene transcription, while the magnitude of change and the number of genes altered increase to certain extent with the increase of time of culture and concentration of HDAC inhibitor (33) (34) (35) . Thus, to identify the characteristic global gene expression changes induced by Apicidin, we performed serial gene expression analysis. Using this approach, we were able to identify 631 genes as Apicidin specific molecular signature that were continuously up-or down-regulated during 48 h of Apicidin treatment (Fig. 2) .
In the present study, we utilized ArrayXPath, a webinterfaced pathway mining tool designed for microarray data (36, 37) , to map and visualize gene expression and to identify the biological pathways affected. This process identified cellcycle regulation as one of the most significant biological processes affected; 11 genes were found to be obviously affected ( Fig. 2B and C) .
Many HDACs have non-histone proteins as their substrates, such as, hormone receptors, chaperone proteins, or cytoskeletal proteins, which are known to regulate cell proliferation and cell death (23) . Thus, HDAC inhibitor-induced cell death involves both transcription-dependent and -independent mechanisms (25, 38, 39) . CDK inhibitor p21
Cip1 is one of the most common genes induced by HDAC inhibitors (40, 41) , and although it was not included among the cell-cycle related 11 genes identified (probably because of missing data), our data indicated that p21
Cip1 was induced by Apicidin, and expression of protein level was confirmed by Western blot analysis. It has been well established that the activation of TGF-ß signaling stimulates the SMAD complex and causes the transcriptional activation of p21 Cip1 and p15 INK4 , which in turn leads to cell-cycle arrest. Thus, the transcriptional activation of the p21 Cip1 might be a consequence of the upregulation of SMAD3 by Apicidin.
Accumulating evidence suggests that HDAC inhibitors induce cell-cycle arrest in normal and transformed cells (25, 42) . Both G1 and G2 arrest are often associated with induction of p21 Cip1 , which inhibits the regulation of G1 progression (CDK4/6) and G1/S transition (CDK2) by inhibiting CDKs. Our array data also showed that CDK4 and CDK6 were specifically down-regulated by Apicidin, and this was supported by Western blot analysis (Fig. 3) . During the G1/S cell-cycle transition, increased CDK inhibitor activity and decreased cyclin may act together to reduce CDK activity and then dephosphorylate Rb, which inactivates E2F and the transcriptions of genes required for G1 progression and G1/S transition are blocked (39) . Interestingly, our data indicate that the E2F1 and DP-1 genes were down-regulated in parallel with the suppressions of CDK4, CDK2 and induction of CDKN1A (p21 Cip1 ) by Apicidin, which implies that Apicidin suppresses cell-cycle progression via the simultaneous transcriptional activation and inactivation of component molecules in the cell-cycle circuit. Indeed, many of E2F/DP-1 downstream target genes, such as, MCMs, DHFR, and PCNA, appeared to be underexpressed (Fig. 4) . In addition, the observed down-regulations of cyclin A2, cyclin B1, B2 and CDC2, which are major regulatory components of the G2/M phase, implies that Apicidin also exerts its anti-proliferative effect by influencing the G2/M transition. In conclusion, the potent anti-mitogenic activity of Apicidin is due to the systemic transcriptional modulation of regulatory components of the cell-cycle circuit.
In summary, this study shows that the anti-tumor activity of Apicidin extends to highly metastatic cancer cells. Furthermore, large-scale DNA microarray data analysis findings showed that 631 genes are substantially modulated by Apicidin suggesting a characteristic molecular signature of Apicidin on MDA-MB-435 cells. Data mining of this molecular signature provides clues concerning the intracellular mechanism underlying the anti-tumor effect of Apicidin. Moreover, comparing these results to the known signaling pathway allows us to explain a systemic regulatory mechanism concerning the G1/S transition (Fig. 4) .
Herein, we suggest that the potent anti-tumor activity of Apicidin is attributable to the modulation of the transcriptomic expressions of molecules in cell-cycle circuit. We hope that further comprehensive analyses of the identified 631 genes and intensive biological validations will provide useful information concerning the mechanisms underlying resistance and sensitivity to HDAC inhibitors. 
